156 related articles for article (PubMed ID: 31848313)
21. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
24. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
Front Immunol; 2021; 12():608292. PubMed ID: 34135884
[TBL] [Abstract][Full Text] [Related]
25. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW
Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.
Chung HC; Ros W; Delord JP; Perets R; Italiano A; Shapira-Frommer R; Manzuk L; Piha-Paul SA; Xu L; Zeigenfuss S; Pruitt SK; Leary A
J Clin Oncol; 2019 Jun; 37(17):1470-1478. PubMed ID: 30943124
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
[TBL] [Abstract][Full Text] [Related]
29. The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.
Nguyen MC; Shah MH; Liebner DA; Backes FJ; Phay J; Shirley LA
J Natl Compr Canc Netw; 2018 Nov; 16(11):1279-1283. PubMed ID: 30442730
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports.
Mota JM; Sousa LG; Braghiroli MI; Siqueira LT; Neto JEB; Chapchap P; Hoff AAO; Hoff PM
Medicine (Baltimore); 2018 Dec; 97(52):e13517. PubMed ID: 30593126
[TBL] [Abstract][Full Text] [Related]
31. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Study of Radiation Therapy in Combination With Pembrolizumab in Patients With Metastatic Renal Cell Cancer.
Lin J; Song AJ; Hoffman-Censits J; Leiby BE; Tuluc M; Shaw C; Harshyne L; Kean R; Bar-Ad V; Den RB; Hurwitz MD; Louie J; Philipose S; Deshmukh SP; Johnson JM; Dicker AP; Hooper DC; Kelly WK; Lu B
Am J Clin Oncol; 2020 Feb; 43(2):82-86. PubMed ID: 31693508
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of pembrolizumab in patients with advanced tumors.
van Vugt MJH; Stone JA; De Greef RHJMM; Snyder ES; Lipka L; Turner DC; Chain A; Lala M; Li M; Robey SH; Kondic AG; De Alwis D; Mayawala K; Jain L; Freshwater T
J Immunother Cancer; 2019 Aug; 7(1):212. PubMed ID: 31395089
[TBL] [Abstract][Full Text] [Related]
34. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.
Naidoo J; Schreck KC; Fu W; Hu C; Carvajal-Gonzalez A; Connolly RM; Santa-Maria CA; Lipson EJ; Holdhoff M; Forde PM; Douville C; Riemer J; Barnes A; Redmond KJ; Kleinberg L; Page B; Aygun N; Kinzler KW; Papadopoulos N; Bettegowda C; Venkatesan A; Brahmer JR; Grossman SA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380662
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
[TBL] [Abstract][Full Text] [Related]
38. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.
Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS
J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab for the treatment of colorectal cancer.
Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
[No Abstract] [Full Text] [Related]
40.
van der Veen EL; Giesen D; Pot-de Jong L; Jorritsma-Smit A; De Vries EGE; Lub-de Hooge MN
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
